- cafead May 17, 2019 at 10:22: AM
via Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago.
Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG; OTCQX:RHHBY) showed that the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK led to one complete response (CR), three partial responses (PRs) and one unconfirmed PR among five evaluable pediatric patients with primary CNS tumors.
article source
Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG; OTCQX:RHHBY) showed that the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK led to one complete response (CR), three partial responses (PRs) and one unconfirmed PR among five evaluable pediatric patients with primary CNS tumors.
article source